Last reviewed 2026-04-22 · How we verify

Mecamylamine Oral Tablet

Mecamylamine Oral Tablet is a Ganglionic blocking agent; nicotinic acetylcholine receptor antagonist Small molecule drug developed by Wayne State University. It is currently FDA-approved for Hypertension (historical indication), Smoking cessation (investigational), Tourette syndrome (investigational). Also known as: Vecamyl.

Mecamylamine is a non-selective nicotinic acetylcholine receptor antagonist that blocks neural transmission in the autonomic nervous system.

Mecamylamine is a non-selective nicotinic acetylcholine receptor antagonist that blocks neural transmission in the autonomic nervous system. Used for Hypertension (historical indication), Smoking cessation (investigational), Tourette syndrome (investigational).

At a glance

Mechanism of action

Mecamylamine competitively blocks nicotinic acetylcholine receptors at the ganglia of both the sympathetic and parasympathetic nervous systems. By inhibiting ganglionic transmission, it reduces sympathetic outflow and lowers blood pressure. It has been historically used as an antihypertensive agent and is being investigated for other conditions including smoking cessation and Tourette syndrome.

Approved indications

• Hypertension (historical indication)
• Smoking cessation (investigational)
• Tourette syndrome (investigational)

Common side effects

• Orthostatic hypotension
• Constipation
• Dry mouth
• Urinary retention
• Tremor
• Dizziness

Key clinical trials

• Mecamylamine for Autonomic Dysreflexia Prophylaxis (PHASE4)
• A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (PHASE3)
• A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (PHASE3)
• A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD) (PHASE3)
• A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (PHASE3)
• To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function (PHASE1)
• A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder. (PHASE2)
• Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Mecamylamine Oral Tablet CI brief — competitive landscape report
• Mecamylamine Oral Tablet updates RSS · CI watch RSS
• Wayne State University portfolio CI

Frequently asked questions about Mecamylamine Oral Tablet

Related

• Drug class: All Ganglionic blocking agent; nicotinic acetylcholine receptor antagonist drugs
• Target: All drugs targeting Nicotinic acetylcholine receptors (ganglionic)
• Manufacturer: Wayne State University — full pipeline
• Therapeutic area: All drugs in Cardiovascular; Neurology
• Indication: Drugs for Hypertension (historical indication)
• Indication: Drugs for Smoking cessation (investigational)
• Indication: Drugs for Tourette syndrome (investigational)
• Also known as: Vecamyl

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing